This is an intermediate patient expanded access protocol for treatment of patients with local or metastatic solid tumors with a neoantigen synthetic long peptide vaccine.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-29.